Dopamethyperpax
Brand names,
Dopamethyperpax
Analogs
Dopamethyperpax
Brand Names Mixture
Dopamethyperpax
Chemical_Formula
C56H71N9O23S
Dopamethyperpax
RX_link
http://www.rxlist.com/cgi/generic4/mycamine.htm
Dopamethyperpax
fda sheet
Dopamethyperpax
msds (material safety sheet)
Dopamethyperpax
Synthesis Reference
No information avaliable
Dopamethyperpax
Molecular Weight
1270.28 g/mol
Dopamethyperpax
Melting Point
No information avaliable
Dopamethyperpax
H2O Solubility
Freely soluble as sodium salt (> 200mg/mL)
Dopamethyperpax
State
Solid
Dopamethyperpax
LogP
No information avaliable
Dopamethyperpax
Dosage Forms
Powder for solution (for injection)
Dopamethyperpax
Indication
For use in the treatment of patients with esophageal candidiasis and prophylaxis of Candida infections in patients undergoing hematopoietic stem cell transplantation.
Dopamethyperpax
Pharmacology
Formerly known as FK463, micafungin is a novel antifungal agent. It is a glucan synthesis inhibitor of the echinocandin structural class. The U.S. Food and Drug Administration approved micafungin in March 2005. Micafungin inhibits an enzyme essential for fungal cell-wall synthesis and is fungicidal (lethal) for Candida. Micafungin can be used concomitantly with a variety of other drugs, including the HIV protease inhibitor ritonavir and the transplant medications cyclosporine and tacrolimus.
Dopamethyperpax
Absorption
No information avaliable
Dopamethyperpax
side effects and Toxicity
Intravenous LD50 in rats is 125mg/kg. In dogs it is >200mg/kg. No cases of overdosage have been reported. Repeated daily doses up to 8 mg/kg (maximum total dose of 896 mg) in adult patients have been administered in clinical trials with no reported dose-limiting toxicity. The minimum lethal dose is 125 mg/kg in rats, equivalent to 8.1 times the recommended human clinical dose for esophageal candidiasis based on body surface area comparisons.
Dopamethyperpax
Patient Information
No information avaliable
Dopamethyperpax
Organisms Affected
Aspergillis, Candida and other fungi